Dr. Eddy Wu is the founder and CEO of Arctic Vision, before he founded Arctic Vision, he was the Head of Terns China Biotechnology where he is responsible for directing and overseeing all aspects of R&D activities as well as general management responsibilities. Before Terns, he was the Executive Medical Director at Allergan China where he is responsible for Allergan’s overall R&D, clinical, medical and portfolio strategy for China. Dr. Wu started his career at Novartis, During his tenure in Novartis, he was based in Basel, Hong Kong, and Taiwan and held various positions with increasing responsibilities and gained in first-hand global experience. At the Novartis Headquarter, He served as regional medical director and head of Health Economics & Outcome Research (HEOR) for AMAC (Asia-Pacific, Middle East, & African Countries), China & Japan.
Dr. Wu graduated with a bachelor’s degree in Biochemistry from the Hong Kong University of Science and Technology (HKUST), where he also obtained his Ph.D. in Biochemistry.

Dr. Qing Liu has 16 Years of clinical, scientific research and industry experience of ophthalmology. Before joining Arctic Vision, she served as Head of Clinical Development & Medical Affairs for Alcon Greater China region, and Medical Director of Alcon Asia Pacific Region, following her roles as Head of Eye Care Medical Affairs in Allergan China, and Scientific Lead for Glaucoma in Allergan Asia Pacific Region, where she has led and driven the successful clinical development and launch of a wide range of ophthalmic drugs, devices and OTC products.
Dr. Liu completed the clinical training of Ophthalmology in Wuhan Tongji Medical College in her early career, and was selected to join the European Commission Marie-Curie Research Training Networks for Retina Neurobiology-Vision Regulation research, and received her PhD from Leipzig University of Germany.

York Chen brings 20 years sales and marketing experience focusing in ophthalmic products. Before joining Arctic Vision, he headed Allergan China’s eye care business with full profit & loss responsibility of more than 10 products (Ozurdex, Ganfort, Lumigan, Combigan, Refresh Tears, etc.), covering four different treatment area (Retina/Glaucoma/Stac/Tears). Previously, he was the National Sales Manager at Alcon, leading the sales for multiple projects. Earlier in his career, York served at MSD and Boehringer Ingelheim with extensive experience in management of sales, marketing, distributors, private hospitals, and key accounts. York graduated from Shanghai JiaoTong university with a bachelor's degree in stomatology and obtained his EMBA from China Europe International Business School (CEIBS).

Simon joined Arctic Vision as Chief Business Officer in 2020. He is also an Operating Partner for Pivotal bioVentures. For nearly 20 years, Simon has had helped organizations create, develop, and partner their most innovative programs or acquire strategic assets.
Before joining Arctic Vision, Simon has held strategy and business development leadership roles at 28-7, Tesaro, MedImmune/AstraZeneca, Amgen, Constellation, Massachusetts General Hospital, and L.E.K. Consulting. He has helped those companies transform from R&D to commercial stage, build virtual pipelines, make their first forays into emerging markets, and aggressively move into new therapeutic areas of focus. Simon’s projects have spanned pharmaceuticals, software, and medical devices across many therapeutic areas. His transactional expertise encompasses M&A, global and regional strategic collaborations, co-promotions, platform partnering, and spin-outs.
Simon received his Ph.D. in Biophysics from Harvard and B.S. in Molecular Biology from the University of California, San Diego.

Ms. Chris has over more than 10 years professional working experience across corporate to capital market. She is head of Investor Relations and Public Relations right now, fully in charge of corporate financing, external communications, media strategy, as well as governance compliance at corporate level. Before joined the Arctic Vision, she was the IR lead at I-MAB Biopharma (Nasdaq: IMAB) to oversee pre-IPO IR and played indispensable role for the IPO debut process entirely. Prior to join the health care industry, she worked as analyst comprehensively covering buy side, sell side, and consulting firm.
Chris holds a bachelor’s degree from Shanghai University of Engineering Science, and an MBA of Jönköping International Business School.

Ms. Ping Cheng has almost 20 years of experience of financial management, investing and consulting. Before joining Arctic Vision, she has worked as the Finance VP of Ark Biosciences Inc. She started her career as a chartered accountant and corporation tax consultant in Ernest & Young’s financial services office in London after her University degree, and then joined Credit Suisse’s UK securities business as an Equity Analyst. In 2011, She became the Head of Shanghai office of DBS Vickers as its lead analyst covering the China Insurance sectors. Ms. Cheng also worked in corporate buy-out for some China’s largest industrial conglomerates including Fosun International.
Ms. Cheng graduated from School of Management, University of Bradford (UK) with a Bachelor’s degree in 2001. She is qualified as a Chartered Accountant with Institute of Chartered Accountant of Scotland (ICAS) and has a CFA designation.

Dr. Ding is an accomplished scientist with in-depth knowledge and extensive experience in the research and development of ocular cell biology, pharmacology, disease models, drug delivery, pharmacokinetics etc. Prior to joining Arctic Vision, he was the Associate Director of Pharmacology/Biology in Perfuse Therapeutics, managing scientific studies ranging from early discovery to IND-enabling studies. Before that, he was Senior Scientist of Pharmacology in Aerie Pharmaceuticals, where he led the pharmacology group in providing pharmacology data packages and study models to support various clinical studies. Before entering industry, he had served as Senior Research Associate in Duke Eye Center, and postdoc research associate at University of North Carolina at Chapel Hill.
Dr. Ding graduated from University of Science and Technology of China, where he received a Ph.D. in Biophysics and a B.S. in Biology.